Metabolism of dichloromethane (DCM) to formaldehyde (HCHO) via a glutathione S-transferase (GST) pathway is thought to be required for its carcinogenic effects in B6C3F, mice. In humans, this reaction is catalyzed primarily by the protein product of the gene GSTTl, a member of the Theta class of GST, and perhaps to a small extent by the protein product of the gene GSTM1. Humans are polymorphic with respect to both genes. Since HCHO may bind to both DNA and RNA forming DNA-protein crosslinks (DPX) and RNA-formaldehyde adducts (RFA), respectively, these products were determined in isolated hepatocytes from B6C3F, mice, F344 rats, Syrian golden hamsters, and humans to compare species with respect to the production of HCHO from DCM and its reaction with nucleic acids. Only mouse hepatocytes formed detectable amounts of DPX, the quantities of which corresponded well with quantities of DPX formed in the livers of mice exposed to DCM in vivo [Casanova, M., Conolly, R. B., and Heck, H. d'A. (1996) . Fundam. Appl. Toxicol. 31,[103][104][105][106][107][108][109][110][111][112][113][114][115][116]. Hepatocytes from all rodent species and from humans with functional GSTTl and GSTM1 genes formed RFA. No RFA were detected in human cells lacking these genes. Yields of RFA in hepatocytes of mice were 4-fold higher than in those of rats, 7-fold higher than in those of humans, and 14-fold higher than in those of hamsters. The RFA:DPX ratio in mouse hepatocytes incubated with DCM was approximately 9.0 ± 1.4, but it was 1.1 ± 0.3 when HCHO was added directly to the medium, indicating that HCHO generated internally from DCM is not equivalent to that added externally to cells and that it may occupy separate pools. DPX were not detected in human hepatocytes even at concentrations equivalent to an in vivo exposure of 10,000 ppm; however, the possibility that very small amounts of DPX were produced from DCM cannot be excluded, since HCHO was formed in human cells. Maximal amounts of DPX| iV er that might be formed in humans were predicted from the amounts in mice and the relative amounts of RFA in hepatocytes of both species. With predicted DPX UTtr as the dosimeter, the unit risk, the upper 95% 0272-0590/97 $25.00 168 Copyright O 1997 by the Society of Toxicology. All rights of reproduction in any form reserved.
Species-dependent carcinogenic responses to dichloromethane (DCM) as well as individual human differences in the metabolism of this compound pose a challenge in efforts to estimate the carcinogenic risk of DCM to humans. DCM induced hepatocellular and pulmonary adenomas and carcinomas in B6C3F, mice exposed to concentrations of 2000 or 4000 ppm and increased the incidence of benign mammary tumors in F344 rats (Mennear et al, 1988) , but it did not cause cancer in Syrian golden hamsters exposed to concentrations as high as 3500 ppm (Burek et al., 1984) . Epidemiological studies of workers exposed to DCM have not shown a correlation between exposure and the induction of lung or liver cancer (Hearne et al., 1987 (Hearne et al., , 1990 , but inherent differences in the rate at which humans can metabolize DCM via a glutathione S-transferase (GST)-dependent pathway have raised the possibility of genetic differences in susceptibility to DCM-induced carcinogenesis (Thier et al, 1993; Hallier et al, 1993; Pemble et al, 1994) .
The GST pathway was recognized as the route most likely to be responsible for the carcinogenicity of DCM (Green, 1983; Andersen et al, 1987) . The activity of this pathway varies across species in a manner that is consistent with their susceptibilities to tumor induction by DCM (Green, 1989; Reitz et al, 1989) . This pathway is thought to result in the generation of a reactive, presumably mutagenic intermediate. The amount of DCM metabolized via this pathway, calculated using a physiologically based pharmacokinetic (PBPK) model, was proposed as a surrogate for the dose of this intermediate in different tissues (Andersen et al, 1987) . The intermediate was not identified, however, and no DNA adducts resulting from exposure of liver or lung tissues of mice to [
I4 C]DCM were demonstrated Ottenwalder and Peter, 1989) . Subsequently, formaldehyde (HCHO) generated from DCM via the GST pathway was shown to form DNA-protein crosslinks (DPX) in mouse liver but not in the livers of Syrian golden hamsters (Casanova et al, 1992 (Casanova et al, , 1996 . Since mice but not hamsters are susceptible to the induction of hepatocellular tumors (Burek et al., 1984; Mennear et al., 1988) , these results suggested that DPX may be involved in the carcinogenic mechanism.
To understand more clearly the metabolism and covalent binding of DCM in different species, hepatocytes from humans, mice, hamsters, and rats were evaluated with respect to their ability to metabolize DCM to HCHO and to form DNA-protein crosslinks. The hepatocyte model for metabolism and covalent binding was validated by comparing the yields of DPX obtained in mouse hepatocytes with those previously observed in mouse liver in vivo (Casanova et al, 1996) . As a comparative dosimeter for risk assessment, however, DPX were found to be of limited utility because they were detectable only in mouse hepatocytes. A more sensitive biomarker was needed for studies involving human cells. In this article, an alternative biomarker for DCM metabolism, RNA-formaldehyde adducts (RFA), is described that is detectable in hepatocytes from humans, mice, hamsters, and rats.
The study of human cells and tissues is important for risk assessment, but people are known to be genetically variable with respect to their ability to metabolize DCM (Bogaards et al, 1993; Hallier et al, 1993 Hallier et al, , 1994 Pemble et al, 1994; Norppa et al, 1995) . This variability is related to the presence or absence of a Theta-class glutathione 5-transferase known as GSTTl-1 (Meyer et al, 1991; Jemth et al, 1996) , the protein product of the gene GSTT1. [A glutathione 5-transferase of the Mu class, the protein product of the gene GSTM1, was reported to metabolize DCM in rats (Blocki et al, 1994) ; however, the specific activity of this enzyme in homogenates of human liver with DCM appears to be negligible (Bogaards et al, 1993) .] The proportion of individuals in different ethnic groups who carry functional alleles for GSTT1 varies from approximately 36% in Chinese to about 80% in Caucasians and 90% in Mexican-Americans (Nelson et al, 1995) . Whether individuals who carry this gene ("conjugators") are (Thier et al, 1993; Pemble et al, 1994) or are not (Hallier etal, 1993) at greater risk of cancer from exposure to DCM than those who do not carry the gene ("nonconjugators") is controversial. Therefore, in studies that involved human cells, the presence or absence of GSTT1 and GSTM1 genes was determined.
MATERIALS AND METHODS

Chemicals. [
14 C]Dichloromethane (10.4 mCi/mmol; radiochemical purity, 99%) was obtained from DuPont-New England Nuclear (Boston, MA) in break-seal tubes. For in vitro incubations of hepatocytes with dichloromethane, [
14 C]DCM was added to cell suspensions from stock aqueous solutions, which were prepared in the following manner. A break-seal tube containing 12 mCi (74 /il) of [ 14 C]dichloromethane and a small (8-ml) scintillation vial were attached to a vacuum line with Tygon tubing greased with silicone. The line was evacuated, liquid N 2 was placed around the scintillation vial, and [ I4 C]DCM was transferred from the break-seal rube to the vial. When transfer was complete (approximately 10 min), the vial was detached from the line, placed in ice, and capped with a Mininert valve (Pierce, Rockford, IL) containing a short 26-gauge needle to provide a vent for relief of internal pressure as the contents warmed from -196 to 0°C. After the [ 14 C]DCM had thawed, the vial was briefly opened, and 7 ml of ice-cold distilled water was added to the vial. The vial was immediately recapped, the needle was removed, and the Mininert valve was closed. [ l4 C]Dichloromethane was dissolved in the water by sonicating and shaking the vial. Analysis of the vial contents was performed by transferring a 25-fj.\ aliquot of the solution to a 25-ml volumetric flask containing methanol and determining the I4 C content of the flask by liquid scintillation spectrometry. This analysis showed that the transfer efficiency of [ I4 C]DCM from the break-seal tube to the scintillation vial was 99% and that the concentration of [ l4 C]dichloromethane in the stock solution was 0.16 M.
[ l4 C]Formaldehyde (10.0 and 53 mCi/mmol, respectively; radiochemical purity at least 99%) was purchased from DuPont-New England Nuclear as aqueous solutions. The vials were opened and the solutions were placed in screw-capped Reacti-Vials (Pierce, Rockford, IL) that contained a Teflonlined septum. Stock solutions were prepared by diluting the contents of the vials with distilled water. [ l4 C]Formaldehyde concentrations of the stock solutions (29.5 and 8.47 mM, respectively) were determined by liquid scintillation spectrometry.
Chemicals used for the isolation and purification of DNA and RNA from hepatocytes and for the analysis of [ l4 C]formaldehyde covalently bound to DNA and RNA were reported previously (Casanova et al., 1996) . All other chemicals were of the purest grade available commercially.
Laboratory animals. Male B6C3F,/CrlBR mice, Syrian golden hamsters [LAK:LVG(SYR)], and Fischer-344 rats [CDF(F344)/CrlBR] were purchased from Charles River (Raleigh, NC, or St Constant, Quebec, Canada). Animals were acclimated to the animal facility (room temperature 24°C, relative humidity 50%) for at least 12 days before use and were maintained on a 12-hr light:dark cycle. All animals received NIH-07 laboratory diet (Zeigler Bros., Gardners, PA) and tap water ad libitum. The animals were free of rodent pathogens detected in standard viral screens (Microbiological Associates, Bethesda, MD).
Hepatocyte isolation from laboratory animals. Hepatocytes were isolated by a modification of the method of Seglen (1976) , as described by Kedderis and Held (1996) . Briefly, animals were anesthetized with Nembutal (0.2 ml per 100 g body weight ip) at approximately 8:00 AM, the peritoneal cavity was opened, and the vena cava was cannulated with a 20-gauge Angiocath (Becton Dickinson, Sandy, UT). The portal vein was cut, and perfusion was begun in situ at 5 ml/min (mice), 15 ml/min (rats), or 8 ml/ mm (hamsters) using 37°C Hanks' balanced salt solution (without calcium or magnesium) containing ethylene glycol ftiX/3-aminoethyl ether)-iV.iV.Af.yV-tetraacetic acid (EGTA) (0.5 mM) and A f -2-hydroxyethylpiperazine-/V'-2-ethanesulfonate (Hepes) buffer (10 mM), pH 7.3. After 7 min, the perfusate was switched to 37°C Williams' medium E (WME) containing collagenase (0.3 mg/ml) and Hepes buffer (10 mM), pH 7.3. Perfusion was continued for 10 to 12 min, after which the liver was carefully removed and placed in a Petri dish containing 20 ml of collagenase solution. The capsule was gently pulled away with forceps, and the cells were dispersed. The cell suspension was filtered through two layers of sterile gauze and diluted with cold WME, and the cells were collected by centrifugation at 50g for 1 min. The preparation was enriched in viable hepatocytes by centrifugation (8 min) through Percoll (10 ml WME, 9 ml Percoll, and 1 ml of Hanks' solution). Hepatocytes whose viability was less than 80% based on trypan blue exclusion were not used. The hepatocytes were incubated with [
I4 C]DCM as described below.
Human hepatocytes.
Suspensions of freshly isolated (uncultured) human hepatocytes were purchased from the Human Cell Culture Center, Woodbine, Georgia. Samples were used only if they met certain criteria, including (1) they were derived from postpubertal subjects to maximize expression of GST [as described for the rat (Lamartiniere, 1981) ]; (2) the hepatocytes appeared morphologically (microscopically) normal and their viability (trypan blue exclusion) was at least 70%; and (3) the donors did not have degenerative liver disease, and no liver trauma was suffered in accidents (verified by the supplier). Several samples provided by the supplier were rejected owing to low viability or because they were derived from a prepubertal subject; three were accepted. Two of these were obtained from organ donors who were accident victims; the third sample was obtained following a lobectomy to remove a biliary obstruction. Sample 1 was a male Caucasian, 17 years of age; samples 2 and 3 were female Caucasians, 46 and 34 years of age, respectively. The hepatocytes were suspended in WME containing 1 fiM insulin, 15 mM Hepes, 100 U/ml penicillin, 100 /jg/ml streptomycin, 12.5 mM L-glutamine, supplemented with 10% lowendotoxin calf serum, and then were air-shipped to the Chemical Industry Institute of Toxicology in 50-ml centrifuge tubes packed in ice in wellinsulated containers and were delivered by courier. Hepatocytes were collected by low-speed centrifugation and resuspended in WME. The samples were incubated with [
I4 C]DCM as described below within 2 to 3 hr of their arrival. Viabilities of the three samples (trypan blue exclusion) at the start of the experiments were 80, 74, and 87%, respectively. Viabilities at the end of the experiments were 75, 70, and 80%, respectively. ["CVichloromethane. Hepatocytes (4 x 10 6 /ml, 3.0 ml) suspended in WME were placed in 30-ml Erlenmeyer flasks capped with Mininert valves under an atmosphere of 5% CO 2 in air. An aliquot of the stock aqueous solution of [ H C]DCM ranging from approximately 0.05 to 0.3 ml in volume was injected into each flask through the valve, and the flasks were incubated with shaking (60 cycles/min) at 37°C for 2 hr. Two or three replicate flasks of hepatocytes were used at each concentration of [ I4 C]DCM, because preliminary experiments showed that the viability of hepatocytes was not maintained if single, larger flasks were used. The final concentration of [ 14 C]DCM in each flask was determined by withdrawing 50 /il from the headspace after 1.5 hr and analyzing the DCM concentration by gas chromatography as described previously (Casanova et at, 1996) . Amounts of [ I4 C]DCM added to the incubation flasks were sufficiently large that the vapor phase concentration remained virtually unchanged throughout the 2-hr incubation, except for the initial partitioning between gas and liquid phases. The concentration of [ M C]DCM in the aqueous phase containing hepatocytes was calculated from the headspace [
Incubation of hepatocytes with
M C]DCM concentration using the partition coefficient
[DCM],, = 6.0 at 37°C.
The partition coefficient was determined at the above temperature using flasks containing 3 ml of WME plus mouse hepatocytes, 3 ml of WME plus heat-inactivated (70°C for 20 min) mouse hepatocytes, or 3 ml of WME without cells. The presence of cells appeared to slightly increase the solubility of DCM in WME, since the partition coefficient in the presence of cells was 12% larger than in the absence of cells. The partition coefficient measurements showed that equilibration of DCM between liquid and vapor phases was complete within 10 min and thereafter remained constant for at least 2 hr. For the given volumes of liquid (ca. 3.2 ml) and vapor (ca. 26.8 ml) in each flask, approximately 42% of the DCM was dissolved in the aqueous phase.
Incubation of mouse hepatocytes with [
l4 C]formaldehyde Hepatocytes from B6C3F, mice (4 X 107ml, 3.0 ml) suspended in 3 ml of WME were placed in 30-ml Erlenmeyer flasks capped with Mininert valves under an atmosphere of 5% CO 2 in air. An aliquot from one of the stock aqueous solutions of [ l4 C]formaldehyde ranging from 39 to 300 fi\ in volume was injected into each flask through the valve, and water was added to bring the final liquid volumes of all flasks to 3.3 ml. The flasks were incubated with shaking at 37°C for 2 hr. Two replicate flasks of hepatocytes were used at each concentration of [ l4 C]formaldehyde. At the end of the incubation, the flasks were opened, replicate flasks were combined, and the cells were collected as described above. The concentrations of [ M C]formaldehyde in the aqueous phase in these experiments were assumed to be equal to the amounts of [ l4 C]formaldehyde added to each flask divided by the aqueous volume; i.e., volatilization of HCHO from the aqueous to the vapor phase was assumed to be negligible. This assumption was justified on the basis of the Henry's law constant for HCHO in water at 37°C. The value of this constant can be calculated from the data of Betterton and Hoffmann (1988) C]formaJdehyde, the flasks were opened in a hood, replicate flasks were combined, and the volume was brought to 30 ml with cold WME. The cells were collected by centrifugation, and the supernatant was discarded. Lysing solution (9 ml) containing 8 M urea and 1% sodium dodecyl sulfate was added to the pellet, and the cells were ruptured by vortexing. The nucleic acids were sheared by several passages through 18-and 20-gauge needles, and proteins were digested with proteinase K to solubilize the DNA that was crosslinked to proteins (Casanova-Schmitz and Heck, 1983; Casanova et ai, 1989) . The solutions were extracted with an equal volume of chloroform/Zioamyl alcohol/phenol (CIP), then the aqueous phase containing nucleic acids was extracted with diethyl ether. Nucleic acids (DNA and RNA) were purified by hydroxyapatite chromatography (Casanova and Heck, 1987 ) DNA was incubated with ribonuclease A (0.33 mg/ml) and washed by ultrafiltration to remove residual nbonucleotides.
The nucleic acids were heated (70°C) overnight, then were enzymatically hydrolyzed (2-3 hr) to deoxyribonucleosides or ribonucleosides in 0.1 M Tris buffer, which resulted in the quantitative release of [ 14 C]formaldehyde (Casanova et ai, 1989 ) DNA was hydrolyzed as described previously; RNA was hydrolyzed using the same enzymes as were used for DNA plus ribonuclease A (0.67 mg/ml). Analysis of the nucleic acid hydrolyzates by high-performance liquid chromatography (HPLC) (Casanova et ai, 1989) showed that both DNA and RNA were completely hydrolyzed to their corresponding nucleosides and that no l4 C-labeled adducts were detectable in either hydrolyzate. The released [ l4 C]formaldehyde was collected in a single tube, acidified to pH 4.8 with acetate buffer, and precipitated with dimedone in the presence of carrier unlabeled HCHO (Casanova el ai, 1989) . Precipitation efficiencies of [ l4 C]formaldehyde under the experimental conditions were determined separately in each experiment and were at least 90%. Dimedone precipitates were collected on filters, the precipitates were dissolved in Hionic-Fluor (Packard, Meriden, CT), and the quantities of [' 4 C]formaldehyde were determined by liquid scintillation spectrometry. Analysis of DNA and RNA was performed by integration of deoxyribonucleoside or ribonucleoside peak areas at 260 nm, and the amount of nucleoside in each peak was computed from standard curves that spanned the range of interest.
Contribution of RNA-Protein crosslinks to RNA-formaldehyde adducts.
To determine whether the [ l4 C]formaldehyde covalently bound to RNA was due to the formation of RNA-protein crosslinks, hepatocytes were incubated for 2 hr with [ I4 C]DCM (concentration in the aqueous phase = 3.2 mM), and then the cells were lysed with sodium dodecyl sulfate-8 M urea as described above. The lysed cells were extracted with CIP before digesting the proteins with proteinase K, which partitioned the nucleic acids into aqueous (AQ) and interfacial (IF) fractions; proteins were mainly extracted into the organic phase (Casanova-Schmitz and Heck, 1983; Casanova-Schmitz et at, 1984; Casanova et al., 1989) . Nucleic acids crosslinked to proteins were assumed to be present in the IF fraction, as shown previously (Casanova-Schmitz and Heck, 1983; Casanova-Schmitz et ai, 1984; Casanova et at, 1989) . The nucleic acids in the IF fraction were solubilized by digesting the proteins with proteinase K. Both AQ RNA and IF RNA were purified by hydroxyapatite chromatography and were washed by ultrafiltration (Casanova-Schmitz and Heck, 1983; Casanova-Schmitz et al., 1984) . Following enzymatic hydrolysis of the RNA, the quantity of released [ 14 C]formaldehyde was determined as described above (Casanova et al., 1989) .
Analysis of glutathione S-transferase genes in human hepatocytes. A
polymerase chain reaction (PCR) method was used to detect the presence of GSTT1 in human cells. Another glutathione S-transferase gene, GSTM1, was also identified, although as mentioned previously, the protein product of this gene may not be involved in the metabolism of DCM (Bogaards et al, 1993; Blocki et ah, 1994) . The multiplex PCR procedure used has been published previously (Chen el al., 1996) . Briefly, this method is a modification of methods used for analysis of GSTM1 (Bell et al., 1993) and GSTTI (Pemble et al., 1994) that includes both sets of GST primers in the same PCR with an annealing temperature of 62°C. /J-Globin primers were added as an internal reference control to monitor the success of each reaction.
RESULTS
DNA -protein Crosslinks in Mouse, Hamster, Rat, and Human Hepatocytes Incubated with
The results of experiments designed to detect covalently bound [
l4 C]formaldehyde in the DNA of mouse, hamster, rat, and human hepatocytes are depicted in Fig. 1 . The range of aqueous DCM concentrations was chosen on the basis of PBPK model simulations (Andersen et al., 1987) that predicted the time-weighted-average concentrations of DCM expected to occur in mouse liver during a 6-hr inhalation I4 C]DCM. DPX formation was detectable in hepatocytes of male B6C3F, mice but not in hepatocytes of F344 rats, Syrian golden hamsters, or humans with or without functional GSTTI genes (see text). A DCM concentration of 1.9 mM is equivalent to the time-weighted-average concentration expected to occur in mouse liver dunng a 6-hr exposure to 4000 ppm, according to a PBPK model (Andersen eta!., 1987) . exposure. For example, the predicted time-weighted-average concentration of DCM in mouse liver during a 6-hr exposure to 4000 ppm is 1.9 mM, which is near the midpoint of the concentration-response curve (Fig. 1) . Concentrations of [ I4 C]DCM in the aqueous phase were calculated from the measured concentrations in the vapor phase by assuming a liquid/vapor phase partition coefficient equal to 6.0 (see Materials and Methods).
As shown in Fig. 1 , DPX were detectable only in mouse hepatocytes. In these cells the yield of DPX appeared to increase in direct proportion to the concentration of DCM in the medium to concentrations at least as high as 2 mM. The line shown in the figure is a linear least-squares regression (through the origin) of the mouse DPX data on the DCM concentration. Although a simple linear model fits the DPX response of mouse hepatocytes satisfactorily, this does not rule out the possibility of a more complex concentration dependence. Note that DPX were not detected in human hepatocytes even at aqueous DCM concentrations as high as 5 mM, which is equivalent to the time-weighted-average concentration predicted to occur in mouse liver during a 6-hr exposure to a DCM concentration > 10,000 ppm.
RNA-Formaldehyde Adducts in Mouse, Hamster, Rat, and Human Hepatocytes Incubated with [ I4 C\Dichloromethane
The results of the analysis of RFA in mouse, hamster, and rat hepatocytes are shown in Fig. 2a . Hepatocytes from all species formed measurable amounts of RFA, with mouse hepatocytes producing about 4-fold higher yields of RFA than rat hepatocytes and about 14-fold higher yields than hamster hepatocytes. Formation of RFA appeared to be linearly related to the concentration of DCM in the medium.
The lines drawn in the figure are linear least-squares regressions (through the origin) of the RFA data on the DCM concentration.
Results obtained using three samples of human hepatocytes are depicted in Fig. 2b . Note that the RFA data for human hepatocytes (Fig. 2b) are shown on an expanded scale relative to that used for rodent hepatocytes (Fig. 2a) . Two of the human samples, denoted as H-l and H-2, produced measurable quantities of RFA. The third sample, denoted as H-3, produced no detectable RFA, indicating that the hepatocytes in this sample did not metabolize [
I4 C]DCM to [ l4 C]formaldehyde. As discussed below, samples H-l and H-2 were obtained from individuals whose DNA contained GSTT1 and GSTM1 genes; sample H-3 was obtained from an individual whose DNA lacked both genes. The yields of RFA in the two human hepatocyte samples that produced this adduct (H-l and H-2) were about one-seventh of those in mouse hepatocytes. (Pankow et al, 1991a,b) , implying that these hepatocytes were metabolically competent. HCHO is not an intermediate in the P450 pathway (Gargas et al., 1986) On average, the ratio of RFA to DPX in mouse hepatocytes was about 9.0 ± 1.4 (JT ± SE, n = 7). If DPX had been formed in GS777-positive human cells, and if the RFA:DPX ratio in human cells were the same as in mouse cells, then DNA-protein crosslinks should have been detected in human hepatocytes; i.e., the expected yield of DPX in human cells would have been above the detection limit of the analytical method. (The same conclusion also applies to cells from the rat and hamster; i.e., DPX should also have been found in these species.) Therefore, the RFA:DPX ratio in human, rat, and hamster hepatocytes was greater than 9.0 ± 1.4.
Contribution of RNA-Protein Crosslinks to RNAFormaldehyde Adducts
To estimate the amount of RNA-protein crosslinks that may be present in RFA, mouse hepatocytes were incubated with [
14 C]DCM, and then the RNA was fractionated into aqueous and interfacial portions by extraction with CIP (see Materials and Methods). The AQ RNA and IF RNA were separately purified by hydroxyapatite chromatography. After enzymatic hydrolysis of the RNA, the amount of [ I4 C]-formaldehyde covalently bound to each RNA fraction was determined (Table 1) . Fig. 3b . Figure 3 demonstrates that the relative amounts of HCHO bound to mouse DNA and RNA depend on whether the formaldehyde was added directly to the medium or was generated internally as a metabolite of DCM. When HCHO was added to the medium (Fig. 3a) , the ratio of RFA to DPX was 1.1 ± 0.3 (Z± SE, n -9), which was almost an orderof-magnitude smaller than the ratio obtained when the hepatocytes were incubated with DCM (9.0 ± 1.4; see above). Thus, at a given yield of DPX, the yield of RFA was much smaller when HCHO was added externally to cells than when it was generated internally by metabolism of DCM. Moreover, the concentration dependence of DPX and RFA formation in mouse hepatocytes was apparently nonlinear when HCHO was added directly to the medium (Fig. 3a) , but it appeared to be linear when HCHO was generated intracellularly from DCM (Fig. 3b) .
PCR Analysis of GSTT1 and GSTM1 in Human Hepatocytes
The results of the PCR analysis of glutathione 5-transferase genes in the three human hepatocytes samples are shown in lanes 1, 2, and 3 of Fig. 4 . Both H-l and H-2 were found to possess GSTT1 and GSTMJ genes, and since the cells produced formaldehyde from DCM (Fig. 2b) , GSTT1 was clearly functional. In contrast, H-3 did not appear to contain either gene. All human samples produced a fragment from the /3-globin gene (internal reference standard), which showed that the PCR procedure was successful and that measurable amounts of DNA were produced. The presence of GSTT1 in samples H-l and H-2 and the absence of this gene in sample H-3 are consistent with the fact that RFA derived from DCM were detected only in the first two sam- Results from multiplex PCR analysis of GSTT1 and GSTM1 are shown. GSTT1 null genotypes lack a 480-bp PCR product (lanes 3 and 6). GSTM1 null individuals lack a 215-bp PCR product (lanes 3 and 5). All samples produced a fragment from the /9-globin gene (internal reference standard). Lanes 5 and 6 are positive/negative controls for GSTT1 and GSTM1. B designates PCR reagent negative control. M is *X 174 //inDIII marker.
pies. The results of Figs. 2b and 4 suggest that samples H-1 and H-2 were derived from conjugators, but that sample H-3 was obtained from a nonconjugator.
DISCUSSION
The Hepatocyte Model: Validation and Limitations
To validate the hepatocyte model, the DPX yields measured in vivo in mice exposed to 4000 ppm (Casanova et ai, 1996) were compared with those obtained in vitro in mouse hepatocytes incubated with [ I4 C]DCM at an aqueous concentration equivalent to the time-weighted-average concentration of DCM predicted to occur in mouse liver at this exposure concentration. As noted previously, the PBPK model (Andersen et al., 1987) predicts that the timeweighted-average concentration of DCM in the liver of a 28-g mouse during a 6-hr exposure to 4000 ppm should be about 1.9 mM.
The yield of DPX in mouse liver at the end of a 6-hr exposure to 4000 ppm of DCM was approximately 29.5 ± 8.9 pmol/mg DNA (JT± 95% CL) (Casanova et al., 1996) . In comparison, the yield of DPX in mouse hepatocytes at the end of a 2-hr incubation with 1.9 mM DCM was 6.6 ± 2.2 pmol/mg DNA (Fig. 1) . Assuming that the yield of DPX increases linearly with time, the expected yield of DPX following a 6-hr exposure of hepatocytes would be 19.9 ± 6.7 pmol/mg DNA. The predicted yield is about 70% of the observed in vivo value. These results support the hepatocyte model as a semiquantitative tool for the investigation of DPX formation. The in vivo-in vitro difference in DPX yields may be due to uncertainties in the intracellular concentrations of DCM or to differences in the metabolic rate constants of DCM and HCHO.
Although the yields of DPX in mouse hepatocytes were similar to those in mouse liver, the formation of DPX was an apparently linear function of the DCM concentration in vitro to concentrations as high as 2 DIM (equivalent to an in vivo exposure of ~4000 ppm) (Fig. 1) , but it was a nonlinear function of the DCM concentration in vivo in this concentration range (Casanova et al., 1996) . However, freshly isolated hepatocytes are considerably less stable than normal liver cells, they lack normal cell-to-cell communications and other interactions with neighboring cells, and they are suspended in a nutrient medium that differs from that in the liver. Therefore, the two systems should not necessarily display identical metabolic or kinetic characteristics. Reasonably close similarities in metabolic behavior of isolated hepatocytes and whole animals have been reported for a few compounds Kedderis et al., 1993; Kedderis and Held, 1996) .
Species Differences in the Formation of DNA-Protein Crosslinks in Hepatocytes
Hepatocytes from B6C3F, mice, a species that is susceptible to DCM-induced hepatocarcinogenesis, formed DPX when incubated with DCM, but no DPX were detected in the hepatocytes of rats, hamsters, or humans. The in vitro results for the mouse and hamster are consistent with in vivo data on DPX formation in which mice but not hamsters formed DPX (Casanova et al., 1996) . The absence of detectable DPX in human hepatocytes (including hepatocytes from individuals carrying the GSTT1 gene), even at DCM concentrations that in mice would be equivalent to an exposure concentration > 10,000 ppm, strongly suggests that if DPX are formed at all in human cells, the amounts must be very much smaller than in mice. This conclusion also applies to rats and hamsters. Thus, among all species tested, the mouse appears to be uniquely capable of forming DPX from DCM.
The present findings on DPX formation in hepatocytes from mice, rats, hamsters, and humans are consistent with observations of Graves et al. (1995) regarding the formation of DNA single-strand (ss) breaks in hepatocytes from these species. These investigators detected DNA ss breaks in mouse hepatocytes incubated with DCM at aqueous concentrations 5= 0.4 mM, which are similar to the concentrations at which DPX were detected in mouse hepatocytes (Fig. 1) . Graves et al. (1995) also observed the formation of DNA ss breaks in rat hepatocytes, but only at concentrations 5= 30 mM. According to Graves et al. (1995) , DCM concentrations above 30 mM are equivalent to in vivo concentrations > 86,000 ppm, which exceed the acute lethal concentration of DCM in rodents. Graves et al. (1995) did not observe DNA ss breaks in either hamster or human (n = 8) hepatocytes at concentrations as high as 90 or 120 mM, respectively. Thus, only mouse hepatocytes were capable of forming either DPX or DNA ss breaks at concentrations below 5 mM.
RNA-Formaldehyde Adducts: An Alternative Dosimeter Related to the Activity of GST with Respect to DCM
RNA exists in cells in a variety of forms, including heterogeneous nuclear RNA, messenger RNA, transfer RNA, and ribosomal RNA and its precursors (Alberts et al., 1983) . The different forms of RNA are compartmentalized, with most of the RNA being ribosomal (ca. 75%) and the remainder being nuclear (ca. 10%) or cytoplasmic (ca. 15%). The particular RNAs to which HCHO is bound may therefore depend on the subcellular locations in which HCHO is produced. The yield of RFA may depend on the rates of HCHO generation and detoxication, the local concentration and types of RNA, and the rate of RNA turnover.
RNA-formaldehyde adducts are a novel dosimeter for formaldehyde that offers the advantage of greater sensitivity than DPX, at least for measurements of HCHO production from DCM. The structures of RFA remain to be determined. As noted previously, the [ l4 C]formaldehyde linked to RNA does not seem to have been bound primarily as RNA-protein crosslinks. Therefore, the HCHO may have been bound as intramolecular RNA-RNA crosslinks [structures of one relatively stable cyclic guanosine-formaldehyde adduct and of two guanosine-formaldehyde-guanosine crosslinks have been reported (Kennedy et al., 1996) ] or as RNA crosslinked to small molecules. Hydroxymethyl adducts are possible but are regarded as unlikely, because these adducts are unstable (McGhee and von Hippel, 1975a,b) , and they would probably not have survived the purification procedures. The term RNA-formaldehyde adducts is intended to denote all forms of HCHO that were detected by the analytical procedure.
As shown in Fig. 2 , there were significant differences among species with respect to the yields of RFA obtained in mouse, rat, hamster, and human hepatocytes incubated with DCM. Specifically, the yields of RFA in rat, hamster, and human hepatocytes with GSTT1 (H-l and H-2) were about l/4th, 1/14th, and l/7th, respectively, of those in mouse hepatocytes. Similarly, Reitz et al. (1989) reported that the activities of GST with respect to DCM in cytosolic preparations from livers of rats, hamsters, and humans with GST activity (n -3; one of four samples had no measurable activity) were about l/4th, l/20th, and l/9th, respectively, of that from livers of mice. Thus, the yields of RFA in hepatocytes appear to be correlated with the activity of GST with respect to DCM.
Another parameter that could affect the rate of DCM metabolism in hepatocytes is the intracellular concentration of glutathione (GSH). The concentration of GSH in hepatocytes varies among species, with values ranging from 129.6 ± 11.5 nmol/10 6 cells in B6C3F, mice (Ruch et al, 1989) to about 50 nmol/10 6 cells in Sprague-Dawley rats (Jones et al, 1978) , 22.3 ± 4.9 nmol/10 6 cells in Syrian golden hamsters, and 21.4 ± 2.6 nmol/10 6 cells in human cells (n = 4) (Steinmetz et al, 1988) .' Hence, the range of GSH concentrations in hepatocytes from mice to hamsters and humans is approximately 6-fold, which together with differences in the specific activity of GST (Green, 1989; Reitz et al, 1989) could explain the differences observed in RFA formation in hepatocytes of different species. The generation of RFA from DCM in human hepatocytes appears to depend on the presence of GSTT1. The number of human samples used in this study was small and in itself would not be compelling evidence for an essential role for this gene; however, the present findings are supported by several other human studies that have demonstrated interindividual differences in GSTT1 and have shown that the presence or absence of this gene can explain differences in the metabolism or genotoxicity of DCM: (1) Hallier et al. (1993) , n = 10: five hemolyzate samples lacked GST activity, and sister chromatid exchange (SCE) induction in lympocytes incubated with DCM was inversely related to this activity; (2) Hallier et al. (1994) , n = 13: six hemolyzate samples lacked GST activity with respect to DCM; (3) Pemble et al. (1994) , n = 8: four hemolyzate samples lacked GST activity with respect to DCM, and the blood samples lacked GSTT1; (4) Norppa et al. (1995) , n = 20: eight erythrocyte samples lacked GST activity with respect to DCM, and the blood samples lacked GSTT1. Thus, including the present study, the total number of individual human samples characterized with respect to DCM metabolism and GSTT1 or susceptibility to SCE induction by DCM in vitro is currently 54, of which 24 lacked the ability to metabolize DCM or were more susceptible than metabolically competent samples to SCE induction by DCM in lymphocytes.
The most extensive studies of human variability with respect to DCM metabolism suggest the existence of two subpopulations of conjugators with low and high GST activity, respectively, the difference in mean activities of the two subpopulations being about a factor of 3, and the overall range from lowest to highest being about a factor of 10 [Bogaards et al. (1993) , n = 22: three liver samples had no measurable GST activity; Hallier et al. (1994) , n = 13 (see above); Norppa et al. (1995) , n = 20 (see above)]. To date, over 800 humans have been characterized with respect to the presence or absence of GSTT1 (Nelson et al., 1995) , but comparisons among humans, mice, rats, and hamsters with respect to the metabolism or genotoxicity of DCM are relatively few [Reitz et al. (1989) : 4 human samples; Green (1989) : 12 human samples; Graves et al. (1995) : 8 human samples; this work: 3 human samples], i.e., 27 human sam-' Measurements of GSH in hepatocytes of mice (104 nmol/10 6 cells) and hamsters (30 nmol/10 6 cells) undertaken in this laboratory according to Sedlak and Lindsay (1968) were similar to values reported in the literature. Note that intracellular glutathione is compartmentalized (Smith et al, 1996) and exhibits diurnal fluctuations. To minimize the possible effects of such changes, hepatocytes were isolated from rodents at the same time each day. pies in total, of which only 7 (Reitz et al., 1989 ; this work) provide a quantitative interspecies (human-mouse) comparison. The present study is the only one to our knowledge in which DCM metabolism in human cells from a potential target tissue was determined together with GSTT1.
Evidence for Different HCHO Pools When HCHO Is Added Directly to the Medium or Generated Metabolically from DCM
The ratio of RFA to DPX in mouse hepatocytes treated with DCM was 9.0 ± 1.4, whereas the RFA:DPX ratio in cells treated with HCHO was 1.1 ± 0.3 (Fig. 3) . The difference in these ratios indicates that HCHO generated internally from DCM is not equivalent to that added externally to cells, and it suggests that separate pools and different concentrations of HCHO are produced from these two sources of HCHO. The reasons for the dependence of the RFA:DPX ratio on the source of HCHO are not well understood. Possible explanations might include compartmentalization of DCM metabolism, HCHO metabolism, RNA, or all three. Moreover, different types of RNA may be bound to HCHO depending on the intracellular localization of the compound. Differences in the intracellular concentration of HCHO may explain the fact that the concentration-response curves for DPX and RFA formation were nonlinear when HCHO was added directly to the medium but appeared to be linear when HCHO was generated internally from DCM.
Further studies should be undertaken to understand the basis for the differences in covalent binding to nucleic acids when HCHO is generated intracellularly by metabolism or is added directly to cells. Given the present findings, however, caution should be used when interpreting studies designed to compare the types of DNA damage induced by HCHO when added externally to cells with those induced by DCM, which have led some authors to conclude that HCHO is not responsible for the genotoxicity of DCM (Graves et al., 1994a (Graves et al., ,b, 1996 Guengerich et al., 1995; . Such a conclusion may be unwarranted. The two forms of formaldehyde do not occupy the same pool, and their relative reactivities with macromolecules appear to be quite different.
Implications for Human Risk Assessment
The absence of detectable DPX in human hepatocytes carrying GSTT1 and GSTMI genes, even at extremely high concentrations of DCM, indicates that humans are far less likely than mice to form this potentially mutagenic adduct from DCM; however, the possibility that very small amounts of HCHO may react with DNA in human cells cannot be excluded, since HCHO was generated from DCM in GS777-positive human hepatocytes. Assuming that DPX were formed in these cells, the maximal quantities that might be produced in human hepatocytes can be Approaches to the risk assessment of DCM using DNA-protein crosslinks (DPX) as the dosimeter. The left side (human dose estimate) shows a procedure for estimating DPX UvCT in humans involving (I) prediction of the AlIC^ for DCM in humans exposed for 6 hr using a PBPK model (Andersen et ai, 1987) ; (2) calculation of DPX in mouse liver containing the same time-weighted-average concentration of DCM (Casanova et ai, 1996) ; (3) estimation of DPX in human liver by multiplying the value of DPX DvCT in mice by 1/7 (see text). The right side (risk assessment) shows two procedures (LMS method and BMD method) to estimate human risk based on an empirical relationship between DPX Lvt , and the mouse tumor response observed at 2000 and 4000 ppm (Casanova et ai, 1996; Mennear et ai, 1988) . In the LMS method (U.S. EPA, 1986), lifetime risk estimates (MLE and UCL) for exposures 6 hr/day, 5 days/week, are calculated by application of this relationship at the concentrations of interest. The risks are adjusted for the duration of exposures. In the BMD method (U.S. EPA, 1996) , the ED, 0 and LED, 0 are calculated from the empirical relationship, and a linear extrapolation is made from the LED, 0 to zero dose, zero risk. The extrapolation provides the upper bounds on the risk at the exposure concentrations of interest. The margin of exposure (dimensionless) is the ratio of the LED I0 to the exposure concentration of interest (see text).
HUMAN DOSE ESTIMATE
estimated by the method outlined in Fig. 5 . The resulting maximal estimate of DPX can be used as an internal dosimeter to provide an upper bound on the likelihood of cancer for humans with metabolic characteristics similar to those of subjects H-l and H-2.
The use of DPX as a dosimeter for risk assessment is based on the assertion that DPX are a measure of the area under the curve (AUC) of reactive formaldehyde in target cells (Hernandez et al., 1994) . According to the U.S. Environmental Protection Agency (U.S. EPA), DPX may be used as a surrogate for the internal dose "whether DPX are mechanistically involved in the carcinogenic process or are simply an indicator of intracellular exposure" (Hernandez et al., 1994) . Thus a defined role for DPX in the carcinogenic mechanism is not an essential requirement for using DPX as a dosimeter.
The left side of the figure describes a method to estimate the amount of DPX that might be formed in the livers of GS7T7-positive humans with metabolic capabilities similar to those of subjects H-l and H-2. The yields of DPX in human liver can be predicted from the quantities of DPX in mouse liver and the relative amounts of RFA in hepatocytes of both species. This calculation assumes that the RFA:DPX ratio in human hepatocytes is identical to that in mouse hepatocytes (9.0 ± 1.4) (Fig. 3b) ; however, since the RFA:DPX ratio in human hepatocytes was > 9.0 ± 1.4, and the yield of RFA in hepatocytes from subjects H-l and H-2 was about one-seventh of that in mouse cells, it follows that the yield of DPX in human hepatocytes was less than one-seventh of that in mouse hepatocytes. Nevertheless, a value of 1/7 is assumed for the amount of DPX in GSTT1-positive human hepatocytes relative to mouse cells. Ideally, a much larger number of human samples should be measured to develop a more precise estimate of the maximum yield of DPX in human hepatocytes; however, the value of 1/7 is consistent with other data on the relative activity of GST in liver cytosolic preparations from humans and mice, i.e., 1/9 (Reitz et al., 1989) and <l/9 (Green, 1989) , and as a maximal estimate of DPX that might be formed in human liver, it is health-protective.
The prediction of DPX in human liver involves (1) calculation of the AUC of DCM in human liver (JJ.M X hr) during a 6-hr exposure to a selected airborne concentration of DCM using a PBPK model (Andersen et al., 1987) ; (2) estimation of the yield of DPX (pmol/mg DNA) that would be formed in the liver of a male B6C3F, mouse if the liver of the mouse 9.6 x 10-* 4.85 x 10~3 2 X 10"' 9 x 10"' 3 x 10" 10-" Risk calculations were based on predicted values for DPX bVCT in humans, although DPX were not detectable in human hepatocytes. The unit risk based on DPX Ure as the measure of exposure was assumed to be the same as that in mice [3. 25 X 10~2 (pmol/mg DNA)" 1 ] (Casanova et al, 1996) . The corresponding unit risk (in units of per ppm) is 1 X 10" 6 ppm"' (see footnote 2).
* Calculated using a version of the PBPK model of Andersen et al. (1987) appropriate for a 70-kg human (R. Conolly, personal communication).
' Predicted using extended PBPK model for DCM in mouse liver (Casanova et al, 1996) , assuming that DPX,,«, in humans = DPX Um in mice X 1/7 at the same time-weighted-average concentration of DCM in the liver of both species.
d Risk estimated for exposure to DCM occurring 6 hr/day, 5 days/week. ' Adjusted risk for exposure occurring 8 hr/day, 5 days/week, 48 weeks/ year, for 45 years.
•'Calculated using Eq. (1) assuming q\ = 1.83 X 10" 2 (pmol/mg DNA)" 1 ) (see text) and extra risk = 0.1.
' Calculated using Eq. (1) assuming q\* = 3.25 X 10" 2 (pmol/mg DNA)~' (see text) and extra risk = 0.1 * Based on linear extrapolation from LED, 0 to zero dose, zero risk. ' The margin of exposure (dimensionless) is the ratio of the LED, 0 (pmol/ mg DNA) to the exposure concentration of interest expressed in the same units.
contained the same time-weighted-average concentration of DCM (Casanova et al., 1996) ; and (3) adjustment of the calculated DPX| iver in mice for the assumed amount of DPX that might be formed in humans (multiplication of mouse DPX| iVCT by 1/7). These steps are shown on the left side of Fig. 5 . Calculated AUC hVCT and predicted maximal DPX liver values in humans at three airborne concentrations of DCM (10, 30, and 100 ppm) are shown in Table 2 .
Two approaches to estimate human risk based on DPX hvCT are shown on the right side of Fig. 5 . One approach uses the linearized multistage (LMS) model, which until recently was the preferred method of the U.S. EPA (1986) . The other approach is based on the benchmark dose (BMD) method (Crump, 1984) , which was proposed by the U.S. EPA (1996) as an improvement on the earlier procedure.
Both approaches begin with an empirical relationship between the "extra risk" of liver tumors in male B6C3F, mice exposed to 2000 or 4000 ppm of DCM in a carcinogenicity bioassay (Mennear et al., 1988) and the concentrations of DPXi.ve,. in male mice exposed to the same concentrations of DCM for 6 hr. The empirical relationship extra risk = = 1 -exp(-,;D).
was found to apply in the observable range of concentrations that induced measurable increases in tumor yields and DPX in mouse liver [see Fig. 4b of Casanova et al. (1996) ]. In Eq.
(1), p(D) is the probability of tumors at dose D [D = DPX hvcr (pmol/mg DNA)], p(0) is the spontaneous liver tumor incidence observed in unexposed male mice, and q\ is the dose coefficient [(pmol/mg DNA)" 1 ]. The maximum likelihood estimate (MLE) of q\ and the upper 95% confidence limit (UCL) on this estimate (denoted by q\* and defined as the "unit risk") for mice were calculated using the program GLOBLU 86 (December 1990 version; Clement International Corp., K. S. Crump Division, Ruston, LA) (see footnote d of Table 6 of Casanova et al., 1996) . For ease of reference, the values of both constants are repeated here: q\ = 1.83 X 10~2 (pmol/mg DNA)"'; q\* = 3.25 X 10~2 (pmoVmg DNA)"
1 .
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Substitution of the predicted value of DPX|, ver in humans in Eq. (1) permits the estimation of the "lifetime risk" of DCM-induced liver cancer for humans (with the same metabolic characteristics as subjects H-l and H-2) who are exposed to DCM for 6 hr/day, 5 days/week, based on the LMS 2 The unit risk (^i*) in units of (pmol/mg DNA) ' can be converted to units of ppm"' as follows. The pharmacokinetic results obtained for mice (Casanova et al., 1996) suggest that the yield of DPX is almost linearly proportional to the exposure concentration at very low DCM concentrations. Therefore from row 2 of Table 2 , assuming a similar proportionality for humans, the relationship between DPX^ (pmol/mg DNA) and the exposure concentration of DCM (ppm) at low airborne concentrations a 3 X 10"' pmol/mg DNA per ppm. The unit risk for mice in units of (pmol/mg DNA)~' is assumed to be identical for humans, i.e., 3.25 x 10~2 per pmol/mg DNA. Hence, the unit risk in units of ppm"' for humans based on DPX, lwr as the measure of exposure is 3.25 X I0" 1 x 3 x I0" 5 a 1 X 10" 6 per ppm. This unit risk is approximately 1600-fold smaller than that calculated by the U.S. EPA (1994) using the PBPK model-estimated amount of DCM metabolized via the GST pathway (Andersen et al., 1987) and adjusting the dose for humans with a surface area correction factor. model (Table 2 ). This calculation assumes that the same equation [Eq. (1)] applies to humans as to mice, i.e., that the unit risk for mice in (pmol/mg DNA)" 1 is the same as that for humans. This assumption is not necessarily valid; i.e., a given quantity of DPX nvCT may or may not represent the same risk for humans as for mice. Thus, humans may differ from mice not only in the dose delivered to DNA (assumed to be 1/7, a pharmacokinetic difference), but also in the consequences that might result from delivery of that dose (a possible pharmacodynamic difference). Whether humans and mice differ in the latter sense is unknown, but in the absence of evidence to the contrary, it is usually assumed that humans and mice are equally sensitive at a given delivered dose. 3 The lifetime risk can be adjusted if the duration of exposure is shorter than 70 years. For example, if the exposure occurs daily in the workplace (8 hr/day, 48 weeks/year) for 45 years [assumed to be one working life (U.S. Occupational Safety and Health Administration, 1987)], the correction factor would be 8/6 X 48/52 X 45/70 = 0.79 (Fig. 5) . The values of the adjusted risk at three exposure concentrations of DCM are shown in Table 2 . 4 In the BMD method, the effective dose corresponding to a 10% response (ED, 0 ) or the lower 95% confidence limit on the effective dose corresponding to a 10% response (LED IO ) can be calculated from Eq. (1) by solving for DPX Uver using either q\ or q\*, respectively, as the dose coefficient when the extra risk is equal to 0.1. Values of ED| 0 and LED, 0 for male B6C3F, mice exposed to DCM are given in Table 2 . In the revised risk assessment guidelines of the U.S. EPA (1996) , the LED IO is taken as a "point of departure" from which a straight line is extrapolated to zero dose, zero risk for genotoxic carcinogens (Fig. 5) . The linear extrapolation can be used to calculate the upper bound on the risk at any given dose at low doses. As shown in Table  2 , the upper bounds on the risk at 10, 30, and 100 ppm are 3 The assumption that the unit risk in units of (pmol/mg DNA) ' is the same for humans and mice is probably a poor one. The spontaneous incidence of liver cancer in male B6C3F, mice is over 40% (Mennear et ai, 1988) , which is much higher than the incidence of liver cancer in humans [<l% (Peters, 1976; Young and Pollack, 1982) ]. Thus, mice are genetically predisposed to develop liver rumors, and potentially mutagenic compounds that can react with DNA may initiate cell transformation more readily in mouse liver than in human liver. 4 Alternatively, instead of adjusting the risk based on the duration of exposure, a time-averaged dose can be calculated. The latter method was used by the U.S. EPA in its recent risk assessment of formaldehyde, although adverse effects from HCHO are known to be associated with the dose rate (intensity of exposure) much more closely than with the total dose (Hernandez et ai, 1994) . Time-averaging the dose has the disadvantage that potentially important nonlinear pharmacokinetic phenomena may be obscured. Therefore, we have chosen to maintain the dose unchanged and to adjust the risk based on the duration of exposure. essentially identical to the UCL on the risk estimated by the LMS method.
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Another parameter that can be calculated using the BMD method is the margin of exposure (MOE), which is defined as the ratio of the LEDio to the exposure concentration at any given concentration of interest (U.S. EPA, 1996) . MOEs at 10, 30, and 100 ppm are shown in Table 2 . According to the U.S. EPA (1996) , knowledge of the margin of exposure could be of benefit to risk managers attempting to decide whether a given exposure concentration represents a significant risk. The MOE values shown in the table apply, of course, only to subjects having metabolic characteristics similar to those of subjects H-l and H-2.
CONCLUSIONS
The present studies have shown that human hepatocytes, like those of mice, rats, and hamsters, can metabolize DCM to HCHO, and that one result of HCHO generation is the formation of RFA. The ability of human cells to metabolize DCM is dependent on the presence of functional GSTT1 genes. In human cells that carry this gene, the yields of RFA were about 7-fold lower than the yields obtained with mouse cells. In rat and hamster hepatocytes the yields of RFA were approximately 4-and 14-fold lower, respectively, than in mouse hepatocytes. Similar results were obtained by Reitz et al. (1989) for the activities (relative to that of mice) of GST with respect to DCM in liver cytosolic preparations from humans, rats, and hamsters.
The amount of HCHO bound to RNA relative to the amount bound to DNA in mouse hepatocytes depends on whether the HCHO is generated internally by metabolism of DCM or is added externally to cells. The RFA:DPX ratio was about 9.0 ± 1.4 when HCHO was produced by metabolism of DCM, but it was 1.1 ±0.3 when HCHO was added directly to cells. This difference indicates that HCHO produced from DCM is not equivalent to HCHO added directly to cells. Therefore, to assume that the toxic effects of HCHO added externally to cells are predictive of those induced by HCHO when it is generated internally by metabolism may be incorrect.
Only mouse hepatocytes were able to form detectable amounts of DPX. DPX were not detectable in GSTT1 -positive human cells, even at aqueous DCM concentrations equivalent to an exposure concentration > 10,000 ppm. The RFA:DPX ratio in human cells was greater than that in mouse cells. If DPX were formed at all in human cells, the amounts were very much lower than in mouse cells. 3 According to the U.S. EPA (1996) , the linear extrapolation procedure (BMD method) gives upper bounds on the potential risk at low doses that are not significantly different from the UCLs predicted by the LMS method. The same conclusion was reached by Krewski et al. (1984) . The results in Table 2 are consistent with these statements.
Whether or not DPX are involved in the carcinogenic mechanism of DCM, they can be used as a dosimeter for risk assessment (Hernandez etai, 1994) . A quantitative relationship between mouse liver tumors and DPX| iVCT has been reported [Eq. (1)] (Casanova et ai, 1996) . Assuming that DPX are formed in GS777-positive human liver, that the amount of DPX in human liver is as high as one-seventh of that in a mouse liver with the same time-weighted-average concentration of DCM, and that the relationship between liver tumors and DPX hver observed in mice also applies to humans, the risk of liver cancer to humans with the same metabolic capabilities as those in the present study can be assessed using predicted values of DPX llver as an internal dosimeter. Since the predictions of DPX llver are maximal values, and since humans are far less likely than B6C3F, mice to develop hepatocellular carcinomas, the resulting risk assessments should provide an upper limit on the likelihood of liver cancer induction in people with similar metabolic characteristics.
